Decrease of Pdzrn3 is required for heart maturation and protects against heart failure

Mathieu Pernot1, Béatrice Jaspard-Vinassa1, Alice Abelanet1

  • 1Univ. Bordeaux, Inserm, UMR1034, Biology of Cardiovascular Diseases, 1 Avenue de Magellan, 33600, Pessac, France.

Scientific Reports
|January 8, 2022
PubMed

Insights

PDZRN3, an E3 ubiquitin ligase, regulates cardiomyocyte organization. Its dysregulation causes heart failure, but blocking PDZRN3 protects heart function, suggesting it as a therapeutic target.

Area of Science:

  • Cardiology
  • Molecular Biology
  • Cell Biology

Background:

  • Heart failure involves cardiomyocyte (CM) alterations at cell contact sites.
  • Planar cell polarity (PCP) signaling is crucial for CM organization and cardiac function.
  • PDZRN3, an E3 ubiquitin ligase, is implicated in PCP signaling and tissue patterning.

Purpose of the Study:

  • To investigate the role of PDZRN3 in cardiomyocyte polarization and heart failure.
  • To determine if PDZRN3 is a potential therapeutic target for heart failure.

Main Methods:

  • Utilized mouse models with cardiomyocyte-specific PDZRN3 overexpression (OE) and knockout (KO).
  • Analyzed cardiac function, CM morphology, and expression of key signaling molecules (PKC ζ, c-Jun, β-catenin).
  • Examined the subcellular localization of intercalated disk proteins (Cx43, ZO1, Desmoglein 2).

Main Results:

  • Moderate CM PDZRN3 OE induced eccentric hypertrophy and heart failure.
  • CM-specific PDZRN3 KO completely protected against pressure-overload induced heart failure.
  • PDZRN3 signaling altered junction protein localization, impairing CM polarization.
  • PDZRN3 OE affected PKC ζ, c-Jun, and β-catenin levels, consistent with non-canonical Wnt signaling.

Conclusions:

  • PDZRN3 controls a genetic program vital for heart maturation and function.
  • Altered PDZRN3 levels disrupt CM organization and lead to heart failure.
  • PDZRN3 is a novel therapeutic target for preventing and treating heart failure.